Anavex announces publication on oral blarcamesine Phase IIb/III trial

Anavex (AVXL) Life Sciences announced the publication “Oral Blarcamesine Phase IIb/III Trial Confirms Identified Precision Medicine Patient Population – Significant Broad Clinical and Quality of Life Improvements for Early Alzheimer’s Disease Patients” to be available online as a preprint at medRxiv, and in submission to a peer-reviewed medical journal. “This publication of blarcamesine, a once-daily oral small molecule, is very exciting, with demonstrated superior clinical efficacy versus approved therapies and slowed neurodegeneration in early Alzheimer’s patients,” said Marwan Noel Sabbagh, MD, Professor of Neurology, and Chairman of the Anavex Scientific Advisory Board. “Coupled with a strong safety profile and no need for routine MRI monitoring, its unique mechanism of action supports a Precision Medicine approach-potentially benefiting up to 70% of early Alzheimer’s disease patients by targeting genetically relevant populations.”